| Drug ID: | Drug183 |
|---|---|
| Drug Name: | Glepaglutide |
| CID: | 146170995 |
| DrugBank ID: | DB14794 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT00868660 |
| Molecular Formula: | C197H325N53O55 |
| Molecular Weight: | 4316.0 g/mol |
| Isomeric SMILES: | CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H |
| Synonyms: | Glepaglutide; ZP1848; Glepaglutide (USAN); ZP-1848; GLEPAGLUTIDE [USAN]; glepaglutida; glepaglutidum; 914009-86-2; GLEPAGLUTIDE [INN]; GLEPAGLUTIDE [WHO-DD] |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
No molecular structure data available
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT00868660 | Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose | PHASE1 | COMPLETED | Zealand Pharma | Inflammatory Bowel Disease | DRUG: ZP1848 | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Glepaglutide-Loaded Foam for the Induction of Mucosal Healing in the Treatment …
PMID: 39905897
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Glucagon-like peptide 2 (GLP-2) stimulates intestinal growth, repairs mucosa, and enhances epithelial integrity but has a short half-life (7 min). Gl…
Creating Glepaglutide, the First Long-Acting GLP-2 Analogue to Enable a Ready-t…
PMID: 39851172
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Human glucagon-like peptide-2 (hGLP-2) receptor agonists have a benefit for the treatment of short bowel syndrome (SBS) and potentially other intesti…
Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory an…
PMID: 36944922
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Glucagon-like peptide-2 (GLP-2) enhances intestinal repair and attenuates inflammation in preclinical inflammatory bowel disease (IBD) mo…
Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patient…
PMID: 30880176
Year: 2019
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Patients with short bowel syndrome might have impaired postprandial endogenous glucagon-like peptide-2 (GLP-2) secretion, which is requir…